Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ: HRTS)

Ultime notizie per Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ:HRTS)

Healthcare

Other

TEMA ETFs

The investment seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools.

Tema Cardiovascular and Metabolic ETF

Tema GLP-1, Obesity & Cardiometabolic ETF

Tigress Financial analyst Ivan Feinseth maintains Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with a Buy and raises the price target from $58 to $64.

News

Price Target

Analyst Ratings

Tigress Financial Maintains Buy on Travel+Leisure, Raises Price Target to $64

<h2 class="wp-block-heading">Poland: Minister Of Health Signs Regulation Tightening Access To Medical Marijuana</h2>
Minister of Health Izabela Leszczyna signed a new regulation regarding narcotics and psychotropic substances on Oct. 29, significantly tightening access to medical marijuana. The new law will take effect seven days after the announcement, <a href="https://bezprawnik.pl/dostep-do-medycznej-marihuany/">writes</a> Bezprawnik, according to translation.
As <a href="https://www.benzinga.com/markets/cannabis/24/09/40877465/poland-tightens-medical-cannabis-rules-bans-telehealth-prescriptions">previously announced,</a> under the new law, medical marijuana prescriptions cannot be obtained through a telemedicine consultation, unless they are continuations of previously prescribed therapy. Only public facilities are allowed to issue remote prescriptions, while private clinics can't continue to prescribe the therapy remotely. The first medical marijuana prescription can only be obtained in person from a doctor.
The new rules come as the Ministry of Health says medical marijuana has been prescribed too easily.
New regulations will mostly affect less mobile patients, those living in smaller towns, and those who are unable to move around freely.
&#8220;The proposed content in the project aims to modify the amended regulation towards strengthening oversight over the prescription of controlled substances, thus reducing negative social phenomena associated with the misuse of these substances, including their excessive prescription, which leads to drug addiction requiring hospitalization or further pharmacological treatment," per the justification. "Besides the aforementioned health and social consequences, this also leads to increased public healthcare costs.&#8221;
In addition to cannabis products, the list of restricted substances includes morphine, fentanyl and oxycodone.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40754721/poland-ministry-of-health-supports-decriminalizing-possession-of-25-grams-of-cannabis-cultivatio">Poland Ministry Of Health Supports Decriminalizing Possession Of 25 Grams Of Cannabis, Cultivation Of 3 Plants</a>
<h2 class="wp-block-heading">Thailand: New Cannabis And Hemp Rules Expected To Be Finalized In A Year</h2>
Deputy Health Minister Dech-Is Khao Thong and his advisory team met this week with the Department of Thai Traditional and Alternative Medicine to discuss progress on the Cannabis and Hemp Act, <a href="https://www.hfocus.org/content/2024/10/32099">writes</a> Hfocus, according to translation. Thong said he needs to review details and scheduled a clause-by-clause discussion of the draft law.
Dr. Somrak Chingsaman, director-general of the department said it is expected that the law will be finalized within one year under the current administration. Among key items of the new draft law are:
<ul>
<li>Flowering parts are strictly for medical use.</li>
<li>Allowed for research purposes.</li>
<li>Products from flowering parts approved by the FDA can be used for consumption only, exempt from this law.</li>
</ul>
For other uses, such as textiles made from cannabis roots, branches, leaves, or stems, separate ministerial regulations will apply.
Improper medical use carries a 20,000-baht fine ($590) or one year in jail, while unauthorized sales will be punished with 100,000 baht or a one-year jail term.
In June, the Thai government decided to reverse its 2022 marijuana decriminalization decision by <a href="https://www.benzinga.com/markets/asia/24/06/39298781/thailand-unveils-proposals-making-cannabis-illegal-again-and-reduce-meth-possession-limits" target="_blank" rel="noreferrer noopener">relisting parts of the cannabis plant as a narcotic</a>, to go into effect January 1, 2025. While Thailand became the first country in Southeast Asia to allow legal the recreational use of marijuana, it has never been properly regulated, resulting in a proliferation of cannabis shops across the country. In July, however, Charnvirakul confirmed that then-Prime Minister Srettha Thavisin <a href="https://www.benzinga.com/markets/cannabis/24/07/39922637/thailand-will-not-re-criminalize-cannabis-prime-minister-agrees-to-regulate-industry-instead-wha" target="_blank" rel="noreferrer noopener">agreed that proper regulation is a better solution</a> than cannabis re-criminalization.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40713696/thai-deputy-prime-minister-optimistic-about-future-of-cannabis-industry">Thai Deputy Prime Minister Optimistic About Future Of Cannabis Industry</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Japan: Ultra-Strict THC Limits Set New Bar For CBD Products, Testing Global Suppliers</h2>
Japan recently imposed new rules regarding THC limits in CBD products and raw materials used to make them. The limits are among the strictest in the world, <a href="https://hemptoday.net/japans-strict-new-cbd-rules-force-suppliers-to-scramble-for-thc-free-formulations/">writes</a> Hemp Today. New rules are expected to take effect in December 2024.
The limits imposed are said to be 200 to 300 times stricter that the threshold in most other countries which usually allow 0.3% THC limit for all CBD products categories. Under Japan's new rules, THC is allowed at 10 mg/kg (= 0.001% = 10ppm) for oils and powders, and even stricter limits apply to aqueous solutions (0.10mg/kg = 0.00001% = 0.1ppm) and food products (1mg/kg = 0.0001% = 1ppm).
 Read Also: <a href="https://www.benzinga.com/markets/asia/24/10/41426708/70-of-german-physicians-can-now-prescribe-reimbursed-medical-marijuana-more-cannabis-updates-from-it">Japan: Updated Guidelines On THC Limits Don&#8217;t Address All Gaps, Says Expert</a>
The new THC limits pose significant challenges for foreign CBD suppliers already operating in Japan. Global companies such as PharmaHemp (Slovenia), Elixinol and CBDfx (U.S.), Endoca (Denmark), and Naturecan (UK) promote their products as THC-free, but Japan&#8217;s strict standards for transparency and rigorous compliance will put these claims to the test.
Continue reading on <a href="https://hemptoday.net/japans-strict-new-cbd-rules-force-suppliers-to-scramble-for-thc-free-formulations/">Hemp Today</a>.
Read Also: <a href="https://www.benzinga.com/markets/asia/24/09/40845784/japan-criminalizes-cannabis-with-7-year-prison-sentence-medical-marijuana-remains-legal">Japan Criminalizes Cannabis With 7-Year Prison Sentence, Medical Marijuana Remains Legal</a>
<h2 class="wp-block-heading">Australia: Victoria's Medicinal Cannabis Patients Can Now Drive Without Fear Of Automatic License Loss</h2>
Medical marijuana patients in Victoria no longer have to fear that they will automatically lose their licence if caught driving with traces of the substance in their system, <a href="https://www.theguardian.com/australia-news/2024/nov/01/victoria-medicinal-cannabis-law-drivers">reported</a> The Guardian. Now, magistrates can exercise sentencing discretion for drivers who test positive for THC, provided they have a valid prescription for medical marijuana and are unimpaired while driving.
Previously, any detectable THC would lead to a mandatory six-month licence loss and fine, impacting users who took cannabis as prescribed for conditions like cancer or multiple sclerosis. Starting March 1, prescribed users can now explain their circumstances in court, allowing magistrates to decide on licence retention. However, driving with any THC trace remains an offence; the reform only adjusts sentencing discretion.
The change comes after Legalise Cannabis Victoria secured an amendment in the upper house on Thursday night
"Roadside saliva tests can detect tiny traces of THC more than a week after consumption, but these minuscule remnants have negligible impact on driving ability," said Legalise Cannabis MP David Ettershank. "Under the old law the mere presence of this remnant chemical meant a compulsory loss of licence for six months and a steep fine, but the driver had only taken their medicine as directed by their doctor."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40323963/australian-cannabis-producers-eye-european-market-especially-germany-and-france-marijuana-and-me">Australian Cannabis Producers Eye European Market, Especially Germany And France, Marijuana And Menstrual Pain Study Underway</a></li>
</ul>
Photo: Courtesy of OMfotovideocontent via Shutterstock

Cannabis

Victoria's Medical Marijuana Patients Can Now Drive Without Fear Of License Loss & More Cannabis Updates Around The Globe

Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) shares are<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679903/wayfair-announces-third-quarter-2024-results-reports-strong-profitability-in-tandem-with-further-m" rel="noreferrer noopener"> trading lower on Friday.</a>
The company reported third-quarter adjusted earnings per share of 22 cents, beating the street view of 13 cents. Quarterly sales of $2.884 billion (down 2%) topped the analyst estimate of $2.876 billion.
U.S. net revenue was $2.5 billion, down $60 million or 2.3% year over year. International net revenue was $372 million, with constant currency growth unchanged.
&#8220;Once again, we navigated a dynamic consumer environment while driving further discipline on costs to achieve a mid-single-digit Adjusted EBITDA margin for the second quarter in a row,&#8221; said&nbsp;Niraj Shah, CEO, co-founder and co-chairman, Wayfair.&nbsp;
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/41686535/can-blockchain-transform-finance-or-will-banks-like-citi-jpmorgan-wield-it-for-efficiency" rel="noreferrer noopener"> Can Blockchain Transform Finance Or Will Banks Like Citi, JPMorgan Wield It For Efficiency?</a>
Gross profit totaled $873 million (year-ago $917 million), representing 30.3% of total net revenue.
As of September 30, there were 21.7 million active customers, a 2.7% decrease from the previous year.
In the third quarter, 9.3 million orders were delivered, down 6.1% year over year.
&#8220;The core goal across each of our initiatives in 2024 is to foster customer loyalty and spur repeat business while driving economic value,&#8221; Shah added.
Mobile devices accounted for 63% of total orders delivered in the third quarter, up from 61.7% year over year.
The company exited the quarter with cash and equivalents worth $1.3 billion. Inventories as of quarter end totaled $81 million. Long-term debt at the end of the third quarter was $3.061 billion.
Needham analyst Bernie McTernan reiterated Wayfair with a <a target="_blank" href="https://www.benzinga.com/quote/W/analyst-ratings" rel="noreferrer noopener">Buy and maintained&nbsp;a $60&nbsp;price target.</a>
Price Action: W shares are trading lower by 2.6% to $41.72&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41683914/exxon-q3-earnings-11-3-billion-cost-savings-rising-production-dividend-hike-and-more" target="_blank" rel="noreferrer noopener">Exxon Q3 Earnings: $11.3 Billion Cost Savings, Rising Production, Dividend Hike And More</a></li>
</ul>

Earnings

Equities

Guidance

Markets

Movers

General

Wayfair Q3 Results: Earnings Beat Street, But Sales And Customer Base Decline

BWS Financial analyst Hamed Khorsand maintains ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) with a Buy and maintains $30 price target.

ATNI

BWS Financial Maintains Buy on ATN International, Maintains $30 Price Target

RBC Capital analyst Paul Treiber downgrades Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) from Outperform to Sector Perform and lowers the price target from $45 to $33.

Downgrades

OTEX

RBC Capital Downgrades Open Text to Sector Perform, Lowers Price Target to $33

Susquehanna analyst Mehdi Hosseini maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Positive and lowers the price target from $110 to $95.

SIMO

Susquehanna Maintains Positive on Silicon Motion Technology, Lowers Price Target to $95

Susquehanna analyst Charles Minervino maintains Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) with a Positive and lowers the price target from $7 to $6.5.

Susquehanna Maintains Positive on Transocean, Lowers Price Target to $6.5

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Mizuho analyst Anthony Crowdell upgraded the rating for IDACORP, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) from Neutral to Outperform and raised the price target from $102 to $116. Idacorp shares closed at $103.48 on Thursday. <a href="https://www.benzinga.com/quote/IDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Myles Minter upgraded argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Market Perform to Outperform. argenx shares closed at $586.30 on Thursday. <a href="https://www.benzinga.com/quote/ARGX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jason Celino upgraded Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) from Sector Weight to Overweight and announced a $260 price target. Atlassian shares closed at $188.54 on Thursday. <a href="https://www.benzinga.com/quote/TEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Paul Zimbardo upgraded the rating for Xcel Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) from Hold to Buy and raised the price target from $71 to $76. Xcel Energy shares closed at $66.81 on Thursday. <a href="https://www.benzinga.com/quote/XEL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst Christian Schwab upgraded Cohu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHU#NASDAQ">COHU</a>) from Hold to Buy and announced a $30 price target. Cohu shares closed at $24.91 on Thursday. <a href="https://www.benzinga.com/quote/COHU/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TEAM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111859/image-3-1024x521.png" alt="" class="wp-image-625822" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111859/image-3-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111859/image-3-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111859/image-3-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111859/image-3.png 1248w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Upgrades

Trading Ideas

ARGX

COHU

TEAM

This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Susquehanna analyst James Friedman maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Positive and raises the price target from $540 to $605.

Susquehanna Maintains Positive on Mastercard, Raises Price Target to $605

Barrington Research analyst Vincent Colicchio maintains Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) with a Outperform and maintains $17 price target.

ASUR

Barrington Research Maintains Outperform on Asure Software, Maintains $17 Price Target

Susquehanna analyst Bascome Majors maintains Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) with a Neutral and lowers the price target from $165 to $160.

LSTR

Susquehanna Maintains Neutral on Landstar System, Lowers Price Target to $160

Susquehanna analyst Bascome Majors maintains Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) with a Neutral and lowers the price target from $50 to $48.

HUBG

Susquehanna Maintains Neutral on Hub Group, Lowers Price Target to $48

Macquarie analyst Aaron Lee maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and raises the price target from $50 to $58.

RBLX

Macquarie Maintains Outperform on Roblox, Raises Price Target to $58

Susquehanna analyst Shyam Patil maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Positive and raises the price target from $140 to $180.

DASH

Susquehanna Maintains Positive on DoorDash, Raises Price Target to $180

Benchmark analyst Michael Albanese reiterates Malibu Boats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBUU#NASDAQ">MBUU</a>) with a Buy and maintains $44 price target.

Reiteration

MBUU

Benchmark Reiterates Buy on Malibu Boats, Maintains $44 Price Target

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $37 to $25.

ANIK

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $25

Susquehanna analyst Biju Perincheril maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Positive and raises the price target from $144 to $148.

Susquehanna Maintains Positive on ConocoPhillips, Raises Price Target to $148

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Phillip Securities downgraded the rating for PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from Buy to Accumulate but raised the price target from $80 to $90. PayPal shares closed at $79.30 on Thursday. <a href="https://www.benzinga.com/quote/PYPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Meredith Jensen downgraded the rating for Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) from Buy to Hold and announced a $156 price target. Hyatt shares closed at $145.45 on Thursday. <a href="https://www.benzinga.com/quote/H/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Gautam Khanna downgraded Huntington Ingalls Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) from Buy to Hold and announced a $180 price target. Huntington Ingalls shares closed at $184.96 on Thursday. <a href="https://www.benzinga.com/quote/HII/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Andrea Teixeira downgraded the rating for The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) from Overweight to Neutral and lowered the price target from $113 to $74. Estee Lauder shares closed at $68.94 on Thursday. <a href="https://www.benzinga.com/quote/EL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Joel Beatty downgraded argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Outperform to Neutral but raised the price target from $515 to $650. argenx shares closed at $586.30 on Thursday. <a href="https://www.benzinga.com/quote/ARGX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HII stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="516" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111134/image-2-1024x516.png" alt="" class="wp-image-625813" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111134/image-2-1024x516.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111134/image-2-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111134/image-2-768x387.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01111134/image-2.png 1245w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

PYPL

This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

<a href="https://www.cnbc.com/2024/11/01/marc-benioff-in-talks-to-sell-time-inc-to-antenna-group.html">https://www.cnbc.com/2024/11/01/marc-benioff-in-talks-to-sell-time-inc-to-antenna-group.html</a>
<ul>
<li>Greek media company the Antenna Group has begun talks to acquire Time from Marc Benioff.</li>
<li>No deal is assured and the discussions are still early.</li>
<li>Benioff acquired Time for $190 million in 2018.</li>
</ul>
The Greek media company Antenna Group is in talks to acquire Time from <a href="https://www.cnbc.com/quotes/CRM/">Salesforce</a> co-founder <a href="https://www.cnbc.com/marc-benioff/">Marc Benioff</a>, according to people familiar with the matter.
No deal is assured and the talks are still early, said the people, who asked not to be named because the discussions are private.
&nbsp;
"There is no agreement to sell Time," said a Time spokesperson, who declined to comment on the talks with Antenna. An Antenna Group spokesperson didn't respond for comment.
Benioff <a href="https://www.nytimes.com/2018/09/16/business/dealbook/time-magazine-salesforce-marc-benioff.html#:~:text=Time's%20parent%20company%2C%20Meredith%20Corporation,of%20an%20iconic%20media%20brand.">acquired Time in 2018 for $190 million</a>. Early talks with Antenna have centered around a price of $150 million, one of the people said.
The talks come at a particularly turbulent time for legacy media companies, which are trying to stay afloat as digital-first assets amid competition with free services such as YouTube, TikTok and Instagram.
<a href="https://www.cnbc.com/quotes/CMCSA/">Comcast</a> <a href="https://www.cnbc.com/2024/10/31/comcast-is-exploring-separation-of-cable-business.html">announced Thursday</a> it is considering a spinoff of its cable network group. The Washington Post, owned by fellow tech billionaire Jeff Bezos, has lost more than 10% of its subscribers in recent days after deciding it wouldn't endorse a candidate in the U.S. presidential election, <a href="https://www.npr.org/2024/10/29/nx-s1-5170939/more-than-250-000-subscribers-have-left-washington-post-over-withheld-endorsement">according to NPR.</a>
Benioff and his wife, Lynne, bought Time from Meredith Corp., which owned the magazine for less than a year.
&nbsp;
"The Benioffs emerged as the best fit, willing to put journalistic integrity ahead of corporate gains," Alan Murray, chief content officer of the Time Inc. brands at Meredith, said&nbsp;<a href="https://www.nytimes.com/2018/09/16/business/dealbook/time-magazine-salesforce-marc-benioff.html#:~:text=Time's%20parent%20company%2C%20Meredith%20Corporation,of%20an%20iconic%20media%20brand.">at the time</a>.
The Antenna Group <a href="https://www.nytimes.com/2022/07/29/business/media/vice-media-antenna-group.html">nearly acquired</a> Vice Media in 2022 before the company declared bankruptcy. Most of its investments have been Europe-centric, though it has invested in Arianna Huffington's technology company Thrive Global.

Asset Sales

'Marc Benioff Is In Talks To Sell Time To Antenna Group; Antenna Group Is In Talks To Acquire Time From Salesforce' - CNBC

Macquarie analyst Paul Golding maintains Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) with a Neutral and raises the price target from $4.9 to $9.

PTON

Macquarie Maintains Neutral on Peloton Interactive, Raises Price Target to $9

HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside

HRTS: Generating Alpha In Obesity Treatment

Spiraling Obesity Costs Could Be Solved By Ozempic And Other Weight-Loss Drugs

The Case For Active Equity Investing: A Fund Manager's Perspective

ACTV

AFMC

AFSM

AMGN

ANEW

ARKK

ARKQ

ARTY

AVUV

BAPR

BOTZ

CYTK

DTEC

HRTS

IGPT

IVOO

IVOV

KOMP

LRNZ

MAGS

MREO

OZEM

ROBO

ROBT

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSPY

SVAL

SYLD

THNQ

THNR

TMDV

TPHD

TPLC

TPSC

UAUG

UBOT

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USVM

WTAI

Tema ETF Trust Tema Obesity & Cardiometabolic ETF

Comments

Tema GLP-1, Obesity & Cardiometabolic ETF

Notizie

Ultime notizie per Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ:HRTS)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO